These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8447550)

  • 61. Treatment of anti-factor VIII antibodies.
    Blatt PM; White GC; McMillan CW; Roberts HR
    Thromb Haemost; 1977 Aug; 38(2):514-23. PubMed ID: 579493
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Current status and future prospects for the prophylactic management of hemophilia patients with inhibitor antibodies.
    Teitel JM; Sholzberg M
    Blood Rev; 2013 Mar; 27(2):103-9. PubMed ID: 23452718
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Successful induction of immune tolerance by continuous infusion of recombinant factor VIII in a haemophilia A patient with high-inhibitor titres.
    Tamura K; Kanazawa T; Suzuki M; Shioya A; Morikawa A
    Haemophilia; 2006 Jan; 12(1):100-2. PubMed ID: 16409184
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Management of patients with factor VIII inhibitors.
    Lusher JM
    Transfus Med Rev; 1987 Aug; 1(2):123-30. PubMed ID: 2980269
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Acquired factor VIII inhibitors.
    Franchini M; Lippi G
    Blood; 2008 Jul; 112(2):250-5. PubMed ID: 18463353
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The use of non-activated prothrombin concentrate in the management of haemophilia A with factor VIII antibodies.
    Price DA; d'Souza S; Ekert H
    Aust N Z J Med; 1977 Jun; 7(3):286-90. PubMed ID: 269689
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Screening of F.VIII:C antibodies by an enzyme-linked immunosorbent assay.
    Mondorf W; Ehrenforth S; Vigh Z; Last J; Tippmann G; Kreuz W; Scharrer I
    Vox Sang; 1994; 66(1):8-13. PubMed ID: 8146988
    [TBL] [Abstract][Full Text] [Related]  

  • 68. How we treat a hemophilia A patient with a factor VIII inhibitor.
    Kempton CL; White GC
    Blood; 2009 Jan; 113(1):11-7. PubMed ID: 18820129
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Development of factor VIII:C antibodies in dogs with hemophilia A (factor VIII:C deficiency).
    Giles AR; Tinlin S; Hoogendoorn H; Greenwood P; Greenwood R
    Blood; 1984 Feb; 63(2):451-6. PubMed ID: 6419797
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Prostate carcinoma associated spontaneous factor VIII:C inhibitor hemophilia. Successful therapy of severe hemorrhagic complication with porcine factor VIII in a 75-year-old patient].
    Orth T; Schnütgen M; Herr W; Mayet WJ; Dippold W; Wanitschke R; Meyer zum Buschenfelde KH
    Med Klin (Munich); 1997 Apr; 92(4):241-5. PubMed ID: 9221309
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Immune tolerance therapy in patients with acquired hemophilia.
    von Depka M
    Hematology; 2004 Aug; 9(4):245-57. PubMed ID: 15621732
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Factor VIII inhibitor treatment with high doses of F VIII.
    Stenbjerg S; Ingerslev J; Zachariae E
    Thromb Res; 1984 Jun; 34(6):533-9. PubMed ID: 6429891
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Rapid acquisition of immunologic tolerance to factor VIII and disappearance of anti-factor VIII IgG4 after prophylactic therapy in a hemophilia A patient with high-titer factor VIII inhibitor.
    Moorehead PC; Thibeault L; Tuttle A; Grabell J; Dwyre L; Silva M; James P; Lillicrap D
    J Pediatr Hematol Oncol; 2015 May; 37(4):e220-2. PubMed ID: 25411864
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein.
    Groomes CL; Gianferante DM; Crouch GD; Parekh DS; Scott DW; Lieuw K
    Pediatr Blood Cancer; 2016 May; 63(5):922-4. PubMed ID: 26739399
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Maintenance of hemostasis during exodontia in two hemophiliacs with factor VIII inhibitors.
    Zech R; Strother SV
    J Oral Maxillofac Surg; 1983 Jan; 41(1):53-6. PubMed ID: 6217303
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Manifestations of factor VIII inhibitor in the head and neck.
    DellaCroce FJ; Kountakis S; Aguilar EF
    Arch Otolaryngol Head Neck Surg; 1999 Nov; 125(11):1258-61. PubMed ID: 10555699
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Anaphylactic reactions following infusion of factor VIII in a patient with classic hemophilia.
    Helmer RE; Alperin JB; Yunginger JW; Grant JA
    Am J Med; 1980 Dec; 69(6):953-7. PubMed ID: 6160766
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prothrombin complex concentrate (Konyne) in the treatment of hemophilic patients with factor VIII inhibitors.
    Abildgaard CF; Britton M; Harrison J
    J Pediatr; 1976 Feb; 88(2):200-5. PubMed ID: 1249680
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII.
    Nilsson IM; Berntorp E; Zettervall O
    N Engl J Med; 1988 Apr; 318(15):947-50. PubMed ID: 3127711
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Induction of immune tolerance in a 7-year-old hemophiliac with an anaphylactoid inhibitor.
    Harper JL; Gill JC; Hopp RJ; Evans J; Haire WD
    Thromb Haemost; 1995 Oct; 74(4):1039-41. PubMed ID: 8560409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.